Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results

Figures & data

Table 1 Baseline characteristics of patients treated with pirfenidone (n=113). Figures are mean±SD unless otherwise stated

Characteristics	Value	Range
Age (years)	69.6±8.1	43.0–82.0
Males, n (%)	80 (71%)
Body mass index	26.8±4.0	15.6–37.7
Smoking history% (current/former/never)	0/68/32
FEV1/FVC	0.80±0.08	0.55–0.95
FVC (L)	2.84±0.9	1.24–5.45
FVC% predicted	80.3±17.9	46–121
DLCO% predicted	45.9±10.3	18–70
6MWD (m)	445.7±94.1	145–640
Oxygen saturation at rest (%)	96.6±2.1	90–100
Desaturation at 6MWT (%)	9.1±6.5	−31–1
Desaturation < 88% at 6MWT (n)	41

DL_CO: carbon monoxide diffusing capacity, FEV1: forced expiratory volume in 1 sec, FVC: forced vital capacity, SD: standard deviation, 6MWD: 6-min walking distance.

Fig. 1 The component of airflow obstruction among the study participants.

Table 2 Diagnosis of IPF

		Video-assisted thoracoscopic lung biopsy
HRCT	Number	Not performed	Definite	Probable	Possible
Definite	73	64	8	1	0
Possible	34	4	20	3	7
Inconsistent	6	0	6	0	0

Fig. 2 The Kaplan–Meier survival curve with 95% confidence intervals.

Table 3 Adverse events with a frequency of more than 5%

Adverse events	No.	Percent
Nausea	50	44.2
Vomiting	12	10.6
Diarrhoea	25	22.1
Dyspepsia	35	31.0
Decreased appetite	45	39.8
Weight loss	26	23.0
Taste disturbance	7	6.2
Cough	25	22.1
Dizziness	14	12.4
Fatigue	44	38.9
Insomnia	13	11.5
Skin-related reactions	37	32.7
Arthralgia/muscle pain	10	8.8